Latest Hotspot

Phanes Therapeutics Partners with Roche for Clinical Trial of PT217 and Anti-PD-L1 Treatment

11 May 2024
3 min read

Phanes Therapeutics, Inc., a biotechnology firm engaged in cutting-edge cancer drug research and advancement, recently declared the initiation of a clinical supply partnership with Roche. Under this agreement, they will conduct research on PT217, a pioneering bispecific antibody that targets DLL3 and CD47. This study will evaluate the combination of PT217 with Roche's anti-PD-L1 therapy, atezolizumab, in treating patients with small cell lung cancer, large cell neuroendocrine carcinoma of the lung, and neuroendocrine carcinomas outside of the lungs.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序

描述已自动生成

In 2022, the FDA awarded PT217 the orphan drug status for treating SCLC, and it also received the Fast Track designation for its use in extensive-stage small cell lung cancer patients who have shown disease progression after treatment with platinum-based chemotherapy, with or without the inclusion of a checkpoint inhibitor.

Phanes is actively recruiting participants for a multi-center Phase I study on PT217. This trial, referred to as the SKYBRIDGE study, aims to assess PT217's safety, tolerability, pharmacodynamics, and initial effectiveness in individuals with advanced or therapy-resistant cancers that show DLL3 expression.

Phanes' upcoming research phase will explore the efficacy of PT217 as a part of combination therapy for SCLC, LCNEC, and EP-NECs. This stage involves a clinical partnership with Roche to test PT217 together with atezolizumab for treating these conditions.

Rita Laeufle, MD, PhD, Chief Medical Officer at Phanes, expressed enthusiasm about the collaboration with Roche: “Partnering with Roche represents an innovative step forward in treating cancers such as SCLC, LCNEC, and EP-NECs, all of which commonly express DLL3, a critical therapeutic target. The intersecting mechanisms of PT217 and atezolizumab may enhance patient outcomes. This partnership is a significant achievement in Phanes’ mission to pioneer novel cancer therapies.”

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of May 11, 2024, there are 1 investigational drugs for the CD47 and DLL3 targets, including 5 indications, 2 R&D institutions involved, with related clinical trials reaching 1, and as many as 1296 patents.

PT-217 has been granted Fast Track status and Orphan Drug designation. Fast Track status is given to drugs that show potential in addressing unmet medical needs, allowing for expedited development and review processes. Orphan Drug designation is granted to drugs that target rare diseases, providing incentives for their development.

图形用户界面, 文本, 网站

描述已自动生成

What are the adjuvants in vaccines?
"What" Series
3 min read
What are the adjuvants in vaccines?
11 May 2024
Adjuvants are substances used in vaccines to enhance the body's immune response to an antigen.
Read →
Neurocrine Biosciences Launches Phase 1 Trial to Assess NBI-1076986 in Healthy Participants
Latest Hotspot
3 min read
Neurocrine Biosciences Launches Phase 1 Trial to Assess NBI-1076986 in Healthy Participants
11 May 2024
Neurocrine Biosciences, Inc. has launched its Phase 1 clinical trial, marking the first time humans are being evaluated.
Read →
What Does Tirofiban Do?
Pharma Pioneer
3 min read
What Does Tirofiban Do?
11 May 2024
Tirofiban, marketed under the brand name Aggrastat, is a potent medication that belongs to the class of glycoprotein IIb/IIIa receptor inhibitors.
Read →
What ADC-related progress will CStone Pharmaceuticals reveal at the ASCO conference?
Hot Spotlight
2 min read
What ADC-related progress will CStone Pharmaceuticals reveal at the ASCO conference?
11 May 2024
The disclosed CS5001 is an ADC targeting ROR1, featuring a unique design.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.